Influential U.S. drug pricing research group the Institute for Clinical and Economic Review (ICER) has updated its assessment of Eisai’s new Alzheimer's disease drug...

As Johnson & Johnson plows ahead on the spinoff of its consumer health business, several dozen jobs have taken a hit. J&J is cutting 57 positions in its c...

After a brief appearance in the pandemic fight, Regeneron and Sanofi’s Kevzara is back with a new indication. Late Tuesday, the partners said the drug scored an F...

Forty years ago, Genentech developed a process for manufacturing antibodies that proved lucrative for the company as many biopharma firms lined up to license the tec...

Gilead Sciences is no stranger to legal claims surrounding its market-leading HIV franchise. Now, the company and two other major biopharma players are heading to tr...

Bayer has big ambitions for its Berkeley, California, campus, where it plans to invest $1.2 billion over the next 30 years. But even a rapidly growing site is not im...

Hoping to make its new long-acting injectable a standard treatment option for HIV, GSK’s ViiV Healthcare is touting an important win for the launch. In a head-to-...

After an FDA approval last year, Eli Lilly’s diabetes drug Mounjaro has been on fire right out of the gate. Now, the Indianapolis pharma giant says it's re...

When an operational improvement plan is “comprehensive,” layoffs are likely to follow. Such is the case at Spanish blood and plasma specialist Grifols. It unveiled a ...

After a federal appeals court panel voted to shelve Johnson & Johnson’s Texas two-step strategy in its years-long talc litigation, the first plaintiff has stepped...